

PerCP/Cy5.5 anti-human HLA-DR

Catalog # / Size: 2235100 / 100 tests
2235095 / 25 tests

Clone: LN3

Isotype: Mouse IgG2b, κ


Immunogen: human PBL

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with HLA-DR (clone LN3) PerCP/Cy5.5 (filled histogram) or mouse IgG2b, κ PerCP/Cy5.5 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells or 5 μ l per 100 μ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining¹ of frozen sections and formalin-fixed paraffin-embedded sections¹, and immunoprecipitation¹.

Application References:

1. Levacher M, *et al.* 1990. *Clin. Exp. Immunol.* 81:177.
2. Terstappen L, *et al.* 1990. *J. Leuk. Biol.* 48:138.
3. Edwards J, *et al.* 1985. *J. Immunol.* 137:490.
4. van Es A, *et al.*

Description: The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4⁺ T cells.

Antigen References:

1. Levacher M, *et al.* 1990. *Clin. Exp. Immunol.* 81:177.
2. Terstappen L, *et al.* 1990. *J. Leuk. Biol.* 48:138.
3. Edwards J, *et al.* 1985. *J. Immunol.* 137:490.
4. van Es A, *et al.*